Global Spondyloarthritis Competitor Landscape Report 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
11
Global Spondyloarthritis Competitor Landscape Report 2018 Featuring 88 Companies

Dublin, Feb. 04, 2019 (GLOBE NEWSWIRE) -- The "Competitor Landscape: Spondyloarthritis" report has been added to ResearchAndMarkets.com's offering. "Competitor Landscape: Spondyloarthritis", briefings contain evaluations of ongoing development activities within the Spondyloarthritis (SpA) disease market, together with analysis of current & potential future product positioning. Key Highlights from the report

  • Given that only 187 patients are currently enrolled in upadacitinib's Phase II/III SELECT-Axis 1 trial in AS, it is assumed that AbbVie will need to run a Phase III program before filing.
  • Secukinumab's EU label update for PsA will bring it in-line with its US label, and is expected to become a key point of differentiation.
  • Change in primary completion date of the Phase III COAST-X trial is not expected to influence ixekizumab's regulatory timeline in any way, with Lilly stating that it expects to file for regulatory approval of ixekizumab in AS and nr-axSpA, simultaneously, by YE 2018.

Landscape Updates

  • Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies.
  • Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
  • Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.

Appendix

  • Current early-stage SpA pipeline & candidate Watch List'.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Key Topics Covered:

  1. Introduction to Sociable Pharma's Spondyloarthritis (SpA) Competitor Landscape
  2. Executive Summary
  3. Key Events & Landscape Updates
  4. Landscape Updates
  5. Order of Entry
  6. Key Competitor Market Entry Strategies
  7. Lifecycle Development
  8. Key Competitor Direction of Travel'
  9. Pipeline Landscape
  10. Pipeline Summary
  11. Approved Product Development Landscape
  12. Lifecycle Development
  13. Appendix

Companies Mentioned

  • AbbVie
  • AbGenomics
  • Abivax
  • Ablynx
  • ACEA Biosciences
  • Acerta Pharma
  • Akari Therapeutics
  • Akros Pharma
  • Almirall
  • Amgen
  • Asana Biosciences
  • Astellas
  • AstraZeneca
  • Bayer
  • Biocad
  • Bird Rock Bio
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Can-Fite Biopharma
  • Celgene
  • Chemo-Centryx
  • Cyclacel
  • Daichii Sankyo
  • Eddingpharm
  • Eisai
  • Eli Lilly
  • EMD Serono
  • Ensemble Therapeutics
  • Galapagos
  • Genentech
  • Gilead
  • GSK
  • Hanmi
  • Hoffmann-La Roche
  • Hutchison Medi Pharma
  • Innate Pharma
  • Innocare Pharma
  • Istesso
  • Izana Bioscience
  • Janssen
  • Japan Tobacco
  • Jiangsu HengRui
  • Kineta
  • Kyowa Hakko Kirin
  • Leo Pharma
  • Lupin
  • MacroGenics
  • MedImmune
  • Merck
  • Merck KGaA
  • Mesoblast
  • Momenta
  • MorphoSys
  • Morphotek
  • MSD
  • Nektar Therapeutics
  • Novartis
  • NovImmune
  • Noxopharm
  • Nuevolution
  • Oscotec
  • OSE Immuno Therapeutics
  • Pfizer
  • Philogen
  • Principia Biopharma
  • Protalex
  • Reata Pharmaceuticals
  • Regen BioPharma
  • Regeneron
  • Rigel
  • Rottapharm Biotech
  • R-Pharm
  • Sanofi
  • Sareum
  • Sun Pharma
  • Swedish Orphan Biovitrum
  • SynAct Pharma
  • Taiho
  • Taisho
  • Takeda
  • TiGenix
  • UCB
  • Valeant
  • Viela Bio
  • Vitae Pharmaceuticals
  • Vitaeris
  • WuXi
  • Xencor

For more information about this report visit https://www.researchandmarkets.com/research/7...lobal?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Musculoskeletal Disorders Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Suiteify Teams Up With Findity for German Launch

Updated Category News Views 54

Striking a Partnership That Makes Sense Today's deal rolls in like thunder on a quiet afternoon. Suiteify, the master of HR and business software in the DACH region, hooks up with Findity to unleash a new game-changer in Germany. They’re cooking up Suiteify Expense & Travel, and if you're in the mid-sized business space, it’s worth a pause to see how these two horses...

Continue Reading
DentScribe Smashes AI Perio Chart Test with Perfect Score

Updated Category News Views 95

High Stakes in Dental Tech: DentScribe's Impeccable Show The dental tech world just got a jolt, and it's not from your morning coffee. DentScribe, the brains cooking up some AI magic in Sunnyvale, has unleashed a real heavyweight. They dropped the mic on their Periodontal Charting Benchmark 1.0 by acing 68 out of 68 tests without breaking a sweat—literal perfection in...

Continue Reading
Altman Brothers Expand Luxury Real Estate To Florida

Updated Category News Views 28

Shifting the Luxury Real Estate Landscape If there's one thing you learn kicking around the real estate market for decades, it’s that savvy operators know when to make a move. The Altman Brothers, known for shaking up the West Coast luxury real estate scene, just pulled another trick out of their hats. This time, they're heading east, making waves in South Florida, and...

Continue Reading
Pre-Sale Prep: Maximize Your Home's Selling Potential

Updated Category News Views 39

Insights for Sellers: The Road to a Smart Sale Alright, here's the deal: you've got a house to sell, and knowing what to fix up beforehand is like playing a high-stakes game of chess. Miss a move, and it could cost you a chunk of change, or worse, a sale. Enter Rosa Stong, the real estate guru from Becker Stong Real Estate Group, dropping knowledge bombs in a HelloNation...

Continue Reading
Yiddish Prescription Labels Extend Language Access in NY

Updated Category News Views 82

Here's something that might fly under the radar unless you're really in tune with how language impacts healthcare—RxTran's move to include Yiddish on prescription labels might not be rocking financial markets, but it's got a punchy little implication for those of us watching where healthcare intersects with real-world needs. A Push Toward Accessibility Healthcare...

Continue Reading
Mather Promotes Connection with Free Gardening Kits

Updated Category News Views 57

Winter Loneliness No Match for Mather’s Green Thumb Initiative Here's something heartfelt coming out of the Windy City: gardening kits. This ain't your standard Wall Street babble—it's about a nonprofit called Mather trying to shed some light on the colder months by giving seniors in Illinois a damn good reason to be joyfully busy. No boilersuit and tie needed, just a...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 105

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
Azenta's 2026 Gains Mask Deeper Challenges Ahead

Updated Category News Views 38

Azenta's Financial Tangle in Fiscal 2026 You ever feel those moments when the numbers paint a pretty picture, but your gut knows there's more beneath? That's Azenta, Inc. (Nasdaq: AZTA) for fiscal 2026. We’re gazing at a revenue uplift of 5% year over year, hitting $622 million from continuing operations. Great, right? But dig deeper, and the tale isn't all sunshine and...

Continue Reading
State Grid's Green Leap at COP31: Stepping into Action

Updated Category News Views 179

Electrification Takes Center Stage at COP31 Well, the folks over in Antalya are buzzing, and not just about their baklava. At COP31, the conversation's a whirlwind of electrification and industrial parks, and right in the thick of it is State Grid. They're not just pumping out kilowatts anymore; they're turning entire parks into green machines. This ain't just corporate...

Continue Reading
Ecopetrol Prices $2B Bonds Amid Strategic Overhaul

Updated Category News Views 44

Digging Deep into Ecopetrol's Bond Move When a company like Ecopetrol drops a $2 billion bond offering, it's no small potatoes. This isn't just bookkeeping—it's a power move as part of a strategic shift, or at least, that's how they want the market to see it. The numbers look solid, but let's dig into why this matters beyond the flashy headlines. The Bond Offering:...

Continue Reading

Top 5 Most Recently Viewed Articles

GTIA Introduces Significant Charitable Giving Initiative

Updated Category News Views 253

GTIA's Charitable Commitment for 2025 During a notable event at ChannelCon, the Global Technology Industry Association (GTIA) revealed an ambitious plan to contribute $1.5 million to charitable causes in 2025. This pledge includes a noteworthy $50,000 grant awarded to a local nonprofit organization focused on supporting underprivileged youth. The announcement illustrates...

Continue Reading
Revolutionary TIL Therapy Shows Promise for Treating Tumors

Updated Category News Views 40

Advancements in Tumor-Infiltrating Lymphocyte Therapy Turnstone Biologics is at the forefront of developing a cutting-edge approach to combat solid tumors through the innovation of Selected Tumor-Infiltrating Lymphocyte (TIL) therapy. Their next-generation Selected TIL technology is engineered to selectively expand the most effective tumor-reactive T cells, positioning it...

Continue Reading
Arc and Curtin Maritime Forge Alliance for Electric Tugboats

Updated Category News Views 194

Arc Teams Up with Curtin Maritime for Hybrid Tugboats In a significant move towards the future of maritime operations, Arc has announced a substantial contract with Curtin Maritime, highlighting a $160 million deal aimed at producing eight hybrid-electric tugboats. This development represents a pivotal step in the electrification of commercial vessels, promising to...

Continue Reading
MP Materials Surges: Key Factors Behind the 531% Growth

Updated Category News Views 237

MP Materials: A Stellar Performance MP Materials Corp (NYSE: MP) has recently seen its stock skyrocket by an astonishing 531%, particularly from its notable four-year low. This surge, characterized by a robust upward trend over the past months, has captured the attention of investors and industry watchers alike. Two pivotal factors—partnerships with the Pentagon and...

Continue Reading
FP Movement Expands to Savannah: Opening Marks New Era

Updated Category News Views 16

FP Movement Steps into Savannah with New Boutique Alright, folks, there’s something brewing down in the historic streets of Savannah, Georgia. FP Movement, Free People's dynamic activewear line, is unveiling its newest outpost at 217 W Broughton St. on May 22, 2026. This isn't just another storefront—it's a strategic play to capture an uptick in lifestyle-oriented...

Continue Reading